Two-thirds of active ingredients for generic drugs manufactured in Asia: European Study

More than 80 percent of Asia's certificates are held by manufacturers in India and China where the majority of producers are concentrated in just a few states and provinces, the study found.;

Published On 2020-10-08 07:00 GMT | Update On 2020-10-08 07:00 GMT

Berlin: Two-thirds of the active ingredients needed to make generic drugs are manufactured in Asia, a study showed on Wednesday, the latest evidence to underscore Europe's reliance on foreign imports for its medicines.

European governments were rattled at the start of the coronavirus outbreak when India, one of the biggest producers of drug ingredients, banned exports of certain products relevant to the pandemic, prompting concerns about disruptions to supply chains and a shortage of medicines.

Although those fears were largely unfounded, European Union health ministers have vowed to boost local drugs production to safeguard against future bottlenecks.

The study by German generics lobby group Pro Generika analysed the global production of 565 active pharmaceutical ingredients (APIs) and found 63 percent of the quality certificates, which grant them suitable for use in medicinal products, were held in Asia, up from around 31 percent in 2000.

Price pressure and lower regulatory requirements have led to a shift in drugs production from Europe to Asia over the past two decades, Pro Generika said.

More than 80 percent of Asia's certificates are held by manufacturers in India and China where the majority of producers are concentrated in just a few states and provinces, the study found. For more than half of the APIs, there are only a handful of manufacturers worldwide.

Europe holds 31 percent of API certificates, down from 59 percent in 2000 with producers mainly in Italy, Germany, Spain, and France focussing on ingredients with low sales volumes that are complex to manufacture.

Spooked by the pandemic, France in June announced plans to bolster domestic production of medicines with President Emmanuel Macron pledging 200 million euros ($236 million) to help domestic research and manufacturing of medicine.

Austria is also investing money to shore up production at an antibiotics plant owned by Swiss drugmaker Novartis's Sandoz division in Tyrol.

Industry players warn bringing production home may be a complicated process, saying higher labour costs and tougher environmental standards make it impossible to compete with Asian suppliers on price.

Novartis said rather than the proximity of a supplier, it was seeking to establish at least two sources for key ingredients to have fallback options in case of outages.

Dual sourcing is "a clear area of focus versus this idea of localising more manufacturing, which I think is the primary instinct in a lot of health authorities," Maria Soler Nunez, head of group quality at the Swiss drugmaker, said at an online event hosted by the Financial Times.

Merck KgaA Chief Executive Stefan Oschmann told Reuters drug shortages at the start of the pandemic were minimal and it was "unrealistic" to repatriate large parts of the production chain to Europe.

Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

AbbVie seeks USFDA nod for combination regimen of Venclexta, Acalabrutinib for previously untreated patients with Chronic Lymphocytic Leukemia

2025-07-30 05:59 GMT

Two-thirds of active ingredients for generic drugs manufactured in Asia: European Study

More than 80 percent of Asia's certificates are held by manufacturers in India and China where the majority of producers are concentrated in just a few states and provinces, the study found.;

Similar News

Zydus completes acquisition of 85.6% stake in Amplitude Surgical

Sanofi earns orphan drug designation from USFDA for multiple myeloma drug

Govt sets target to open 25000 Jan Aushadhi Kendras by March 2027: Minister

AbbVie seeks USFDA nod for combination regimen of Venclexta, Acalabrutinib for previously untreated patients with Chronic Lymphocytic Leukemia

NPPA Approves Separate Price for GSK's New Paracetamol-Phenylephrine Sachet

Torrent Pharma Gears Up to Launch Oral, Injectable Semaglutide in 2026 Post Patent Expiry: Report

Intas Pharma appoints Umesh Gupta as Associate Executive Vice President - Manufacturing Operations

Raid in Paschim Vihar: Counterfeit medicine racket busted